Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to boost exercise and brain power in heart failure

NCT ID NCT07202000

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether an investigational drug called activin ligand-trap, combined with exercise training, can improve exercise capacity and cognitive function in 48 adults with heart failure with preserved ejection fraction (HFpEF). Participants will receive either the drug or a placebo for 12 weeks. The study measures changes in peak oxygen uptake and cognitive test scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
activin ligand-trap biological therapy (investigational drug)
What this could lead to
If it works, this could point toward a new treatment to improve exercise ability and mental function in people with a common type of heart failure.
What could go wrong
This is an early phase 2 trial with only 48 participants, so results may not apply widely. The drug is investigational and may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.